Lupin is increasing its focus on complex generics, specialty medicines and differentiated products as global patent expiries create opportunities in regulated markets. The company reported growth in ...

Novo Nordisk is losing GLP-1 and diabetes market share in key regions as Eli Lilly's Zepbound and Mounjaro gain U.S. leadership. NVO's latest GLP-1 drug delivered weaker weight loss than Eli Lilly's, ...

New Delhi [India], April 15: India's healthcare sector is poised for high single-digit year-on-year revenue growth in Q4FY26, but EBITDA margins are set to 'materially correct' as the loss of ...

March 31 (Reuters) – Novo Nordisk has again cut the prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 36% and 48% in India, to fend off competition from cheaper ...

President Donald Trump is scheduled to visit Cincinnati on Wednesday to talk up his new prescription drug plan. An Ohio-based expert said there isn’t much novel about it and reporting has shown that ...

Swiss pharma giant Novartis AG NVS reported fourth-quarter core earnings per share (excluding one-time charges) of $2.03, which beat the Zacks Consensus Estimate of $1.99. The figure was also up from ...

This weight-loss leader was drubbed last year. It's a popular pick as a 2026 rebound candidate. More than that popularity, it has credible catalysts to bounce back this year. Fast-forward to 2026, and ...

The fun part about a programming language like C is that although the language doesn’t directly support many features including object-oriented programming and generics, there’s nothing that’s keeping ...